News

Palisade Bio's PALI-2108 Shows Promising Results in UC Trial

Palisade Bio's PALI-2108 Shows Promising Results in UC Trial

Palisade Bio Reports Positive Early Findings for PALI-2108

Initial cohorts of the study highlight the drug's safety and tolerability.

Carlsbad, CA -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical firm specializing in innovative treatments for autoimmune and inflammatory diseases, has released encouraging preliminary data from the initial three single ascending dose (SAD) cohorts involving PALI-2108, evaluated for the treatment of Ulcerative Colitis (UC).

The Phase 1 clinical trial is designed as a single-center, double-blind, placebo-controlled investigation focusing on the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PALI-2108 in healthy participants. Simultaneously, an open-label segment of the study includes patients diagnosed with UC.

So far, data indicate that PALI-2108, administered in varying doses of 15mg, 50mg, and 150mg to 24 subjects (with a 6:2 active to placebo ratio), has shown no treatment-related adverse events, serious adverse events, or laboratory abnormalities associated with the treatment. The preliminary pharmacokinetic analysis exhibits a delayed release profile that corresponds with the drug’s intended colonic bioactivation.

This early data establishes a hopeful foundation for subsequent phases. Palisade Bio plans to move forward with a crossover study aimed at understanding how food intake affects drug absorption, followed by multiple ascending dose (MAD) cohorts. Detailed safety evaluations will continue alongside pharmacokinetic assessments in these upcoming studies.

The primary goal of this Phase 1 trial is twofold: to assess the safety and tolerability in healthy individuals, and to gather data on how PALI-2108 behaves in UC patients. While several PDE4 inhibitors are already approved for certain inflammatory and fibrotic conditions, PALI-2108 stands out as a novel chemical entity, previously unadministered to humans.

Further insights will be obtained through biomarker assessments, including serum high sensitivity C-reactive protein (hsCRP) and fecal calprotectin (CalPro), and through histological evaluations of colon tissues. This comprehensive approach aims to shed light on PALI-2108’s action mechanism and efficacy, focusing on critical drug levels, PDE4 expression, and other pharmacodynamic markers.

Palisade aims to provide topline results from this clinical investigation in the near future, emphasizing its commitment to developing targeted therapies for chronic conditions.

For additional details about the clinical study, prospective participants may refer to clinicaltrials.gov under the identifier NCT06663605.

Understanding PALI-2108

PALI-2108 is distinguished as an orally administered, locally acting, colon-specific PDE4 inhibitor prodrug, specifically tailored for individuals suffering from Ulcerative Colitis. The data collected from ongoing studies is anticipated to bolster Palisade Bio’s precision medicine approach, which aims to identify responsive patient populations for future clinical evaluations.

About Palisade Bio

Palisade Bio is committed to progressing innovative biopharmaceutical solutions aimed at autoimmune, inflammatory, and fibrotic diseases. By focusing on targeted therapies, the company strives to reshape treatment options for patients facing these difficult health challenges.

Palisade's ongoing research highlights their dedication to advancing biomedical science and improving health outcomes for patients relying on cutting-edge medication. They invite the community to learn more about their mission and evolving projects by visiting their website.

Frequently Asked Questions

What is the significance of the Phase 1 trial for PALI-2108?

The Phase 1 trial assesses the safety and tolerability of PALI-2108, crucial for determining its viability for treating Ulcerative Colitis.

What were the initial findings regarding PALI-2108?

Initial findings suggest PALI-2108 is safe and well tolerated with no treatment-related adverse events reported in early cohorts.

How will the trial progress following these findings?

Palisade Bio plans to conduct crossover studies to evaluate food effects on pharmacokinetics, followed by additional cohort studies.

What are the next steps for Palisade Bio regarding PALI-2108?

The company intends to report topline data from the trial in the near future and continue advancing its clinical studies.

What role do biomarkers play in the research?

Biomarkers like hsCRP and fecal calprotectin will provide insights into PALI-2108's effects and the drug mechanisms involved.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 92

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 94

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
AI Governance Is Becoming Enterprise Infrastructure

Updated Category News Views 52

Governance Has Finally Reached the Engine Room Enterprise AI is no longer a shiny pilot parked in some innovation lab; it is creeping into business-critical work, and that changes the argument entirely. Frost & Sullivan’s latest analysis makes a sensible point that too many executives still resist: AI governance is becoming a strategic operating capability, not merely a...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 28

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Home Nursing Plans Need Clarity Before the Next Crisis

Updated Category News Views 71

A medication change scribbled on a loose sheet can become a very long night. That is the unglamorous truth behind the discussion from Michael and Marsha Reda of Aurora Home Care in Williamsville, New York: long-term home nursing care depends on a plan people can actually follow when the household is tired, worried, and juggling too much. Their perspective, featured by...

Continue Reading
Branch's Fast 500 Rank Signals Payroll Platform Reach

Updated Category News Views 89

Six straight appearances on Deloitte's Fast 500 is not random confetti; it says Branch has kept finding customers while plenty of fintech outfits were busy shrinking their ambitions. The Tampa-based workforce-payments company landed at No. 146 in the 2026 ranking, which measures fiscal-year revenue growth from 2022 through 2025. That is a respectable showing in a list...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 81

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
Trade Secret Damages Turn on Corporate Intent Evidence

Updated Category News Views 101

Suspicion may rattle a courtroom, but it apparently does not always loosen the jury’s purse strings. That is the useful, slightly sobering takeaway from DOAR’s new national study on damages in trade secret disputes, released November 20, 2026. Jurors, according to the report, draw a meaningful line between an employee carrying experience to a new job and a company...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 43

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Story Cannabis Bets on Neighborly Thanksgiving Outreach

Updated Category News Views 67

A frozen turkey is not a grand strategy deck, thank goodness; it is dinner for a household that might be feeling the squeeze. Story Cannabis plans to hand out 840 of them on Tuesday, Nov. 24, splitting the giveaway between Columbus and Cleveland with former Ohio State and Dallas Cowboys running back Michael Wiley joining employees and volunteers. In a cannabis business...

Continue Reading

Top 5 Most Recently Viewed Articles

PAPZIMEOS Emerges as the Go-To Treatment for RRP Patients

Updated Category News Views 104

PAPZIMEOS: A Promising New Standard for RRP Therapy PAPZIMEOS (zopapogene imadenovec) has gained recognition as an innovative treatment for adults suffering from recurrent respiratory papillomatosis (RRP). This breakthrough comes following the publication of a consensus paper authored by 16 leading experts in the field. Sponsored by the Recurrent Respiratory...

Continue Reading
Ollie's Bargain Outlet Reports Encouraging Q2 Results

Updated Category News Views 159

Ollie's Bargain Outlet Achieves Strong Q2 Performance Ollie's Bargain Outlet Holdings, Inc. (NASDAQ: OLLI) has made headlines recently as its shares experience fluctuations in the market. The company revealed impressive second-quarter adjusted earnings per share of 99 cents, surpassing analyst expectations of 94 cents. The quarterly sales reached $679.556 million, marking...

Continue Reading
Fivecast Introduces Groundbreaking Discovery Solution for OSINT

Updated Category News Views 184

Fivecast Unveils Discovery Solution to Combat Global Threats In today's rapidly evolving landscape of global threats, Fivecast, a prominent provider of advanced open-source intelligence (OSINT) solutions, has rolled out an innovative Discovery solution designed to assist analysts and investigators in both government and corporate settings. By elevating the speed and...

Continue Reading
Zen Technologies USA Advances Military Training with AI Simulations

Updated Category News Views 224

Zen Technologies USA Showcases Cutting-Edge AI Simulations Zen Technologies USA is set to revolutionize military training capabilities with its next-generation AI-enabled live and virtual simulation solutions. By enabling high-fidelity training for ground and naval forces, these innovations aim to accelerate the readiness of military units while significantly reducing...

Continue Reading
Sectra and Siemens Healthineers Transform Radiology Workflows

Updated Category News Views 494

Revolutionizing Radiology with Innovative Integrations International medical imaging IT and cybersecurity company Sectra (STO: SECT B) and Siemens Healthineers AG have formed a pivotal collaboration aimed at enhancing diagnostic capabilities in the radiology field. This initiative seeks to improve patient care by enabling seamless access to advanced imaging technologies....

Continue Reading